| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PATH.2659 |
| P698 | PubMed publication ID | 19967725 |
| P50 | author | Anne-Marie Mes-Masson | Q30002003 |
| Martin Köbel | Q37839414 | ||
| P2093 | author name string | Jason Madore | |
| Patricia N Tonin | |||
| David Huntsman | |||
| Lilia Sanchez | |||
| Diane M Provencher | |||
| Ali Filali-Mouhim | |||
| Fengge Ren | |||
| P2860 | cites work | Bioconductor: open software development for computational biology and bioinformatics | Q21194861 |
| Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis | Q35098091 | ||
| beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome | Q35787682 | ||
| Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas | Q35842249 | ||
| The p53 tumor suppressor gene frequently is altered in gynecologic cancers | Q40808817 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 392-400 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Journal of Pathology | Q400296 |
| P1476 | title | Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma | |
| P478 | volume | 220 |
| Q55465801 | A Pathological Study Using 2014 WHO Criteria Reveals Poor Prognosis of Grade 3 Ovarian Endometrioid Carcinomas. |
| Q33584346 | A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer |
| Q82477888 | Altered expression and localization of connexin32 in human and murine gastric carcinogenesis |
| Q27313766 | An Immunohistochemical Algorithm for Ovarian Carcinoma Typing |
| Q36145443 | BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group |
| Q37639332 | Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium |
| Q34720998 | Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier |
| Q36790454 | Endometriosis-associated ovarian cancer: a review of pathogenesis |
| Q37025950 | Evaluating cell lines as tumour models by comparison of genomic profiles |
| Q38717253 | Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification. |
| Q54962253 | Hoxa5: A Key Player in Development and Disease. |
| Q36976183 | In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells. |
| Q37082531 | In-depth molecular profiling of the biphasic components of uterine carcinosarcomas |
| Q91366811 | Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5 |
| Q34938333 | Modeling high-grade serous ovarian carcinogenesis from the fallopian tube |
| Q37765470 | Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. |
| Q41685127 | Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures |
| Q100454927 | Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome |
| Q37888659 | Molecular targeted therapy in ovarian cancer: what is on the horizon? |
| Q46364204 | Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups |
| Q37196721 | Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. |
| Q38602953 | Mutational heterogeneity in non-serous ovarian cancers |
| Q36248459 | Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease |
| Q37378287 | Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium |
| Q37328373 | Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies |
| Q35000449 | Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma |
| Q36050883 | Rethinking ovarian cancer: recommendations for improving outcomes |
| Q35815552 | Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk |
| Q26785614 | The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life |
| Q30422138 | The loss of Hoxa5 function causes estrous acyclicity and ovarian epithelial inclusion cysts |
| Q27025315 | The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention" |
| Q33577824 | The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis |
| Q47397232 | Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach |
| Q28536689 | Type-specific cell line models for type-specific ovarian cancer research |
| Q36685324 | YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. |
Search more.